Background and aims: Although regenerating gene (REG) Ia protein may be involved in the inflammation and carcinogenesis in the gastrointestinal tract, its pathophysiological role in ulcerative colitis (UC) and the resulting colitic cancer remains unclear. We investigated expression of the REG Ia gene and its protein in UC and colitic cancer tissues. We examined whether cytokines are responsible for REG Ia gene expression and whether REG Ia protein has a trophic and/or an antiapoptotic effect on colon cancer cells. Methods: Expression of REG Ia mRNA and its gene product in UC tissues was analysed by real time reverse transcription-polymerase chain reaction and immunohistochemistry, respectively. The effects of cytokines on REG Ia promoter activity were examined in LoVo cells by luciferase reporter assay. The effects of REG Ia protein on growth and H 2 O 2 induced apoptosis were examined in LoVo cells by MTT and TUNEL assays, respectively. Results: REG Ia protein was strongly expressed in inflamed epithelium and in dysplasias and cancerous lesions in UC tissues. The level of REG Ia mRNA expression in UC tissues correlated significantly with severity of inflammation and disease duration. REG Ia promoter activity was enhanced by stimulation with interferon c or interleukin 6. REG Ia protein promoted cell growth and conferred resistance to H 2 O 2 induced apoptosis in LoVo cells. REG Ia protein promoted Akt phosphorylation and enhanced Bcl-xL and Bcl-2 expression in LoVo cells. Conclusions: The REG Ia gene is inducible by cytokines and its gene product may function as a mitogenic and/or an antiapoptotic factor in the UC-colitic cancer sequence.
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T he regenerating gene (Reg) was originally isolated from a complementary DNA (cDNA) library derived from regenerating rat pancreatic islets, and its human homologue was named REG Ia. 1 REG Ia protein is predominantly expressed in the normal pancreas, and at lower levels in the stomach and colon, implying physiological roles for REG Ia in these organs. 2 3 Indeed, recent studies have reported that REG Ia is overexpressed in pancreatitis, 4 5 Helicobacter pylori induced gastritis, 6 and in gastric ulcer lesions, 7 8 suggesting that has an important role in the pathogenesis of gastrointestinal inflammatory diseases. Moreover, it is interesting that REG Ia gene was identified as a distinctly overexpressed gene in inflammatory bowel disease by microarray analyses. 9 10 However, it is not clear how REG Ia gene expression is enhanced in such inflammatory conditions.
Although we and others have previously suggested that Reg protein has a trophic effect on mammalian epithelial cells, [11] [12] [13] its biological functions are still unclear. Recently, REG Ia was suggested to be involved not only in inflammatory diseases but also in carcinogenesis in various gastroenterological tissues, such as the stomach, 14 15 colon, 16 bile duct, 17 and pancreas 3 ; however, its involvement in ulcerative colitis (UC) associated colorectal cancer (colitic cancer) is not known. As the REG Ia gene is probably overexpressed in UC, 9 10 REG Ia may play an important role as a trophic or other factor in the development of colitic cancers. In the present study, in order to elucidate the role of REG Ia in the UC-colitic cancer sequence, we investigated the relationship between REG Ia expression and clinicopathological factors in patients with UC and colitic cancer. Furthermore, in in vitro studies, we examined whether cytokines enhance REG Ia gene expression and whether REG Ia has a trophic and/or an antiapoptotic effect on colon cancer cells.
MATERIALS AND METHODS

Tissue specimens and histological examination
Colon biopsy specimens were obtained by endoscopy from 24 patients with UC (15 men and nine women; mean age 45.6 years (range 19-79); mean disease duration 6.4 years (range 0-19)), four patients with Crohn's disease (two men and two women; mean age 36.0 years (range 26-50); mean disease duration 5.5 years (range 0-15)), eight patients with proctitis (six men and two women; age range 40-79 years), 10 patients with sporadic colon adenoma (seven men and three women; age range 55-85 years), and five normal controls (five men; age range 33-38 years) at Kyoto University Graduate School of Medicine. Tissue specimens were used for real time reverse transcription-polymerase chain reaction (RT-PCR) and histological analyses. This work was done with the approval of the Review Board of Kyoto University Hospital, and informed consent was obtained from all patients.
A total of seven colitic cancer lesions (location: five rectum, one sigmoid, one descending; histology: four well differentiated adenocarcinomas, three mucinous adenocarcinomas) were obtained from surgically resected specimens from four UC patients (two men and two women; age range 44-58 years; disease duration 11-25 years) and eight sporadic Abbreviations: Reg, regenerating gene; IFN, interferon; TNF, tumour necrosis factor; IL, interleukin; CINC, cytokine induced neutrophil chemoattractant; UC, ulcerative colitis; TUNEL, TdT mediated dUTP nick end labelling; MTT, 3,-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; WST-8, 2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt; RT-PCR, reverse transcription-polymerase chain reaction; PCNA, proliferating cell nuclear antigen; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; EGFP, enhanced green fluorescent protein gene colon cancer lesions (location: three rectum, two sigmoid, one descending, one ascending, one caecum; two well differentiated adenocarcinomas, six moderately differentiated adenocarcinomas) were obtained from eight non-UC patients (five men and three women; age range 65-79 years) at Dokkyo University School of Medicine. The colitic cancer tissue specimens were fixed in 10% formalin solution, embedded in paraffin, and subjected to histological analyses. Sporadic colon cancer tissue specimens were used for real time RT-PCR and histological analyses. This work was done with the approval of the Dokkyo University Surgical Pathology Committee, and informed consent was obtained from all patients.
The diagnosis of UC was based on established endoscopic and histological criteria, 18 and the degree of inflammation was evaluated according to Matts' grade 18 throughout the experiments.
Immunohistochemical staining
Immunohistochemical stainings for proliferating cell nuclear antigen (PCNA) and REG Ia protein were performed, as described previously, 6 14 using antihuman PCNA antibody (PC10; Dako Japan, Kyoto, Japan; dilution 1:1000) and antihuman REG Ia antibody (dilution 1:2000). 3 A cancerous specimen was considered positive for REG Ia when more than 20% of the tumour cells were positively stained. 14 
Real time RT-PCR
Total RNA was isolated from colonic biopsy samples and seven human colon cancer cell lines (Caco-2, COLO 205, DLD-1, HT-29, LoVo, SW403, and WiDr) with Trizol reagent (Gibco BRL, Rockville, Maryland, USA). Total RNA (5 mg) was reverse transcribed using oligo-dT primer (Applied Biosystems, Branchburg, New Jersey, USA) and RT product was amplified by PCR, as previously described. 6 14 TaqMan quantitative real time PCR was performed with the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, California, USA). The following set of primers and probe for human REG Ia was prepared: human REG Ia 59-CTA GAG GCA ACT GGA AAA TAC ATG TCT-39 (sense), 59-GTT GGA GAG ATG GTC CGG TTT-39 (antisense), and 59-FAM-AAC GGA GTC AAA AAT T (probe). In addition, a set of primers and probe for human glyceraldehyde-3phosphate dehydrogenase (GAPDH) was synthesised by Applied Biosystems.
Each amplification consisted of a 50 ml reaction mixture with 50 ng of cDNA, 250 nM of REG Ia probe (or 100 nM of GAPDH probe), 900 nM of REG Ia primer (or 200 nM of GAPDH primer), and 16TaqMan universal PCR master mixture (Applied Biosystems). PCR cycling conditions were 50˚C for two minutes, 95˚C for 10 minutes, followed by 45 cycles at 95˚C for 15 seconds and 60˚C for 60 seconds. A template free negative control was included in all amplifications, and each assay was performed in duplicate. The intensity of the fluorescent dye was determined, and expression levels of REG Ia mRNA were normalised to GAPDH mRNA expression levels.
Cell culture and treatment
Colon cancer cell lines LoVo and SW403 were routinely maintained in RPMI1640 medium (Invitrogen, Grand Island, New York, USA) with 10% fetal bovine serum (Invitrogen) in a humidified incubator at 37˚C with an atmosphere of 5% CO 2 . These cell lines were used for assessment of REG Ia promoter activity by interferon c (IFN-c; Roche, Mannheim, Germany), tumour necrosis factor a (TNF-a; Roche), interleukin (IL)-1b (Roche), IL-5 (Pepro Tech Inc, Rocky Hill, New Jersey, USA), IL-6 (Roche), IL-8 (Roche), and IL-13 (Pepro Tech Inc). In addition, LoVo cells were used for assays of cell growth and apoptosis.
Luciferase activity assay and transfection
The human REG Ia promoter from 21195 to +78 was generated from human stomach DNA by PCR using the following set of primers containing Mlu I and Bgl II restriction site, respectively: 59-CTT ACG CGT GAA TTC CTG GGC TCA AGT GA-39 and 59'-CCC GAA GAT TTT AGA TCT ACA GTG C-39'. The cloned nucleotides of the promoter were inserted into the position between Mlu I and Bgl II restriction site, upstream of the luciferase gene in the pGL3-Basic vector (Promega, Madison, Wisconsin, USA), and the construct was named hREG Ia-Luc.
LoVo and SW403 cells (2610 4 ) were seeded 24 hours before transfection in 12 well plates (Iwaki, Funabashi, Japan). Cells were cotransfected with 700 ng of a hREG Ia-Luc construct and 7 ng of Renilla luciferase plasmid pRL-TK (as a control of transfection efficiency) in the Optimen medium (Gibco, Grand Island, New York, USA) using FuGENE 6 transfection reagent (Roche, Indianapolis, Indiana, USA) according to the manufacturer's protocol. Forty eight hours later, cells were stimulated by IFN-c, TNF-a, IL-1b, IL-5, IL-6, IL-8, and IL-13 for 3, 6, 12, and 24 hours.
Luciferase assays were performed using the Dual Luciferase Reporter Assay system (Promega) according to manufacturer's protocol. Firefly luciferase and Renilla luciferase activities were assayed by luminometer (Lumat LB 9506; Berthold, Germany). Results obtained were normalised for Renilla luciferase activity and expressed as fold of activity of the untreated cell group at the 0 hour time point.
Transfection and expression of the human REG Ia cDNA
The full length of human REG Ia cDNA was inserted into the pIRES2-EGFP vector containing cytomegalovirus promoter driving the enhanced green fluorescent protein gene (EGFP) (Clontech, Palo Alto, California, USA). After cloning and verifying the nucleotides of the human REG Ia cDNA by sequencing, the construct was named pIRES2-hREG Ia, and pIRES2-EGFP vector without insert was used as a control.
Plasmids were stably transfected into LoVo cells using FuGENE 6 transfection reagent, as described above. To select cells with stable expression of the pIRES2-hREG Ia and pIRES2-EGFP, cells were cultured for over 3-4 weeks in medium containing G418 (Gibco; 400 mg/ml) and surviving colonies were pooled.
Preparation of conditioned medium
To prepare conditioned medium, we cultured human embryonic kidney (HEK) 293T cells in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. According to the manufacturer's protocol, cells were transfected with 10 mg of pIRES2-hREG Ia or control plasmid using FuGENE 6 transfection reagent. The medium was replaced by serum free RPMI1640 medium after a 48 hour incubation period. The conditioned medium was then collected and stored frozen as a source of recombinant REG Ia protein.
Cell growth assay
Cell growth was assessed by Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). LoVo cells (5610 3 ), stably transfected with pIRES2-hREG Ia (LoVo-REG Ia cells) or pIRES2-EGFP (LoVo-EGFP) vector, were plated in 96 well microplates. Cells were incubated in serum free RPMI1640 medium for 24, 48, and 72 hours. After addition of 10 ml of the Cell Counting Kit-8 reagent followed by a three hour incubation, the plates were read at 450 nm in a spectrophotometer (Molecular Devices Co., Sunnyvale, California, USA). To assess the effect of REG Ia in the medium, we added anti-REG Ia antibody (50 mg/ml) to serum free RPMI1640 medium, 13 19 and cells incubated for 72 hours were also evaluated in the same procedure.
Cell growth assay was also performed to examine the trophic effect of REG Ia protein on colon cancer cells. Briefly, LoVo cells (5610 3 ) were cultured in 96 well microplates for 24 hours. Then, the medium was changed to conditioned medium containing human recombinant REG Ia or control medium, and cells were incubated for 24, 48, and 72 hours. To assess the effect of REG Ia in the medium, we added anti-REG Ia antibody to control or REG Ia containing medium, and cells incubated for 72 hours were also evaluated in the same procedure.
TUNEL assay
LoVo-REG Ia cells (1610 4 ) and control LoVo-EGFP cells were cultured in four well culture slides (Falcon, Bedford, Massachusetts, USA). Twenty four hours later, cells were incubated for two hours with different concentrations (0-10 mmol/l) of H 2 O 2 in serum free medium. Thereafter, cells were incubated in routine medium for 24 hours. After wash with phosphate buffered saline, slides were fixed with 10% buffered formalin for 15 minutes and then stained by In Situ Cell Death Detection Kit (Roche) according to the supplied protocol. TdT mediated dUTP nick end labelling (TUNEL) index was calculated as the percentage of positive cells. To assess the effect of REG Ia in the medium, we added anti-REG Ia antibody (50 mg/ml) to routine medium immediately after treatment with H 2 O 2 (5 mmol/l).
TUNEL assay was also performed to examine the antiapoptotic effect of REG Ia protein on colon cancer cells. LoVo cells (5610 3 ) were cultured in four well culture slides for 24 hours, followed by a 24 hour incubation with conditioned medium containing human recombinant REG Ia or control medium. Then, cells were incubated for another two hours with different concentrations (0-10 mmol/l) of H 2 O 2 , and subjected to TUNEL assay 24 hours later. To assess the effect of REG Ia in the medium, we added anti-REG Ia antibody to control or REG Ia containing medium immediately after treatment with H 2 O 2 (5 mmol/l).
Detection of phosphorylated, non-phosphorylated Akt, and Bcl family proteins
LoVo cells were cultured in 10 cm dishes for 24 hours. After washing with phosphate buffered saline, the medium was changed to conditioned medium containing human recombinant REG Ia or control medium, and cells were incubated for another 12 hours. Cells were then mixed with lysis buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40 (NP-40), 50 mM NaF, and 16proteinase inhibitor (Complete Mini; Roche). Protein extract (10 mg) was fractionated by sodium dodecyl sulphate polyacrylamide gel electrophoresis. After transfer to a polyvinylidene difluoride membrane, western blots were performed using anti-Akt, antiphospho specific Akt (Ser473) (New England Biolabs, Beverly, Massachusetts, USA), anti-Bcl-2, anti-Bcl-xL, anti-Mcl-1 (BD Sciences, San Jose, California, USA), and anti-bactin antibodies (Sigma Chemical Co., St Louis, Missouri, USA), as previously reported. 20
Statistical analysis
All values are expressed as mean (SEM). Statistical differences between the two groups were assessed by the unpaired two tailed t test or by the Mann-Whitney U test when data were not parametric. The relationship between REG Ia mRNA level and disease duration was assessed by linear regression analysis. A p value of less than 0.05 was considered to indicate statistical significance.
RESULTS
Expression of REG Ia mRNA in normal colonic and ulcerative colitis mucosa REG Ia mRNA expression was detectable by real time RT-PCR in all colonic mucosa from both control and UC patients. As shown in fig 1A, the level of REG Ia mRNA expression was significantly greater in UC tissues than in normal colonic tissues. Furthermore, levels of REG Ia mRNA expression in Crohn's colitis and proctitis tissues were also significantly greater than that in normal colonic tissues. We next analysed the relationship between REG Ia mRNA expression and several clinicopathological factors, and found that REG Ia mRNA expression was significantly enhanced as the severity of endoscopic or histological features increased ( fig 1B, 1C) . Moreover, REG Ia mRNA expression in UC patients of long duration (>10 years) was significantly greater than those of short duration (,10 years) ( fig 1D) . We further subdivided patients by both disease duration and histological findings and analysed REG Ia mRNA expression in each group. As shown in fig 1E, in high-Matts score group REG Ia gene expression level in patients with long duration UC was significantly greater than that in patients with short duration UC. In addition, in low-Matts score group REG Ia gene expression level in patients with long duration was also greater than in patients with short duration although this was not statistically significant (p = 0.16). REG Ia mRNA expression in UC tissues was significantly correlated with disease duration ( fig 1F) but not with age or sex (data not shown).
Expression of REG Ia protein and PCNA in normal colonic and ulcerative colitis mucosa, and in dysplasia and colitic cancer In normal colonic mucosa, REG Ia immunoreactivity was detected only in a few epithelial cells in the basal portion of crypts (fig 2A) . Colonic epithelial cells positive for PCNA were also observed in the basal portion of crypts ( fig 2B) . In UC mucosa, both the number of REG Ia positive cells in crypts and the intensity of REG Ia immunoreactivity were increased. Strongly REG Ia positive cells were mainly observed in the lower part of the colonic mucosa ( fig 2C) . The number of PCNA positive cells in crypts was also increased, and the distribution of such cells was similar to that of REG Ia positive cells ( fig 2D) .
REG Ia immunoreactivity was detected in the cytoplasm of not only dysplastic but also colitic cancer cells (fig 2E, 2G ). REG Ia expression was detected in all seven of the colitic cancer lesions, originating from four patients examined. PCNA was also strongly expressed in both dysplastic and cancerous cells in all colitic cancer tissues examined (fig 2F, 2H).
Expression of REG Ia mRNA in colon cancer cell lines, sporadic colon adenomas, and cancers
Expression of REGIa mRNA was detected in all seven colon cancer cell lines examined using the RT-PCR method (fig 3) . Then, we examined REG Ia mRNA expression in colon adenomas, cancers, and their neighbouring normal colon mucosa by real time RT-PCR. REG Ia mRNA expression level in colon adenomas (n = 10; 159 (51)) was significantly higher than that in normal colon mucosa (n = 10; 1.0 (0.2)) (p,0.05). Moreover, the REG Ia mRNA expression level in colon cancers (n = 8; 1260 (710)) was significantly higher than that in normal colon mucosa (p,0.05).
Effects of cytokines on REG Ia promoter activity in colon cancer cell lines
The effect of several cytokines on human REG Ia promoter activity was analysed by transient expression assays in two human colon cancer cell lines (fig 4) . In both LoVo and SW403 cells transfected with the hREG Ia-Luc construct, luciferase activity was significantly elevated at three hours after stimulation with IFN-c (100 and 500 U/ml) and this elevation was sustained for 24 hours. Similarly, human REG Ia promoter activity was enhanced in both cell lines at three hours after treatment with IL-6 (100 and 1000 IU/ml) and again the elevation was sustained for 24 hours. In contrast, treatment with TNF-a, IL-1b, IL-5, IL-8, or IL-13 did not affect luciferase activity in the two cell lines.
Effect of REG Ia on cell growth in LoVo cells
LoVo cells transfected with pIRES2-hREG Ia (LoVo-REG Ia) showed significantly higher WST-8 cleavage levels than LoVo cells transfected with pIRES2-EGFP (LoVo-EGFP; control) at each time point (24-72 hours) of incubation ( fig 5A) . 
Antiapoptotic effect of REG Ia in LoVo cells
The LoVo-REG Ia cell group showed significantly lower TUNEL positivity than the LoVo-EGFP group when they were (fig 6A) . The decreased TUNEL positivity in the LoVo-REG Ia cell group was significantly reversed by treatment with anti-REG Ia antibody ( fig 6B) , suggesting that secreted REG Ia protein confers an antiapoptotic effect on colon cancer cells.
LoVo cells treated with REG Ia conditioned medium showed a significantly lower TUNEL positivity than cells treated with control medium when they were exposed to H 2 O 2 at concentrations of 2.5-10 mM ( fig 6C) . The decreased TUNEL positivity in REG Ia treated LoVo cells was significantly reversed by concomitant administration of anti-REG Ia antibody ( fig 6D) .
Treatment with REG Ia conditioned medium enhanced the phosphorylation of Akt in LoVo cells ( fig 7A) . Moreover, REG Ia conditioned medium clearly increased Bcl-2 and Bcl-xL expression in LoVo cells whereas REG Ia did not affect Mcl-1 expression ( fig 7B) .
DISCUSSION
In the present study, we have shown that REG Ia is expressed in only a few small cells in the mid to basal portion of a colonic crypt where putative stem cells reside and continuous cell renewal is occurring. 21 22 Interestingly, in the gastric epithelium, REG Ia is expressed not only in enterochromaffin-like and chief cells but also in immature small cells in the proliferating neck zone of gastric glands. 14 23 As REG Ia protein is indeed mitogenic to gastrointestinal epithelial cells, 11 REG Ia produced in the proliferative zone may play a role in the self renewal of gastrointestinal epithelium under certain physiological conditions. It is noteworthy that several investigators have identified REG Ia as one of the most abundantly expressed genes in the colonic mucosa of patients with UC by gene chip analyses, 9 10 even though only a few REG Ia positive cells are present in normal colonic mucosa. Confirming these data, we demonstrated in this study that levels of both REG Ia gene and its protein were significantly increased in UC mucosa. Furthermore, we also showed that enhancement of REG Ia gene expression in the colonic mucosa was correlated with severity of inflammation in UC, as assessed both endoscopically and histologically. These data strongly suggest that REG Ia is important in the inflammatory process of UC.
What factors could be responsible for the increase in REG Ia expression in UC mucosa? As various cytokines play important roles in the inflammation of UC, we examined in this study whether those cytokines enhance transcription of the REG Ia gene in vitro, and found that both IFN-c and IL-6 significantly stimulated REG Ia promoter activity in colon cancer cells. In contrast, IL-8, IL-1b, TNF-a, IL-5, or IL-13 could not enhance REG Ia promoter activity in colon cancer cells. Previous studies have shown that, in addition to IFN-c and IL-6, TNF-a and CINC-2b, a mouse homologue of IL-8, can enhance REG Ia gene expression in rat pancreatic acinar cells 19 24 and in rat gastric mucosa in vivo. 25 The discrepancies between these results and our present data may be due to the use of different species, cell types, or experimental conditions. It is well known that expression of both IL-6 and IFN-c is prominently increased in UC mucosa. [26] [27] [28] Thus although we did not measure levels of those cytokines in this study, it appears reasonable to suppose that increased levels of IL-6 and IFN-c in the mucosa of UC are at least in part responsible for the enhanced expression of the REG Ia gene and its product. It may be noted that although UC is known as a Th2 dominant disease, 29 30 none of Th2 cytokines tested in this study had any effect on REG Ia promoter activity. These data may suggest that the enhanced REG Ia expression in UC mucosa is not a Th2 specific phenomenon but rather a reflection of a general inflammatory condition where IL-6 and IFN-c expression are elevated.
It is important to clarify whether REG Ia is involved in the carcinogenesis of UC associated colorectal cancer. Interestingly, we found in this study that REG Ia was expressed not only in the epithelial cells of UC mucosa but also in epithelial cells of dysplastic lesions and in colitic cancer cells. Moreover, we have clearly shown that REG Ia expression is significantly increased in patients with longstanding colitis that presents a high risk of colitic cancer. 31 32 These findings strongly suggest involvement of REG Ia in the UC-colitic cancer sequence. During UC, colonic epithelial cells are continuously injured by inflammation that may induce sustained regeneration of epithelial cells. In the present study, we have shown that REG Ia protein has not only growth promoting but also antiapoptotic actions on colonic cells, and moreover that REG Ia protein exerts its antiapoptotic effect at least in part by activating Akt signalling and enhancing Bcl-xL and Bcl-2 expression. Thus REG Ia protein induced by UC may play a role in protecting colonic epithelial cells from apoptosis. Conversely, however, as REG Ia expression is sustained at high levels in chronic UC, its antiapoptotic action as well as its growth promoting effects may contribute to the development of colitic cancer from UC tissues. Of note, we also found that the distribution of REG Ia positive cells was similar to that of PCNA positive cells in colitic cancer tissues as well as in dysplastic and colitis mucosa. Therefore, REG Ia produced in epithelial cells as well as in cancer cells may exert a direct action on epithelial cells in colitis, and also on cancer cells themselves. In support of this view, addition of anti-REG Ia antibody to the incubation medium abolished not only the growth promoting effect of REG Ia conditioned medium but also the enhanced growth of REG Ia transfected cells. Similarly, anti-REG Ia antibody blocked the antiapoptotic effect of REG Ia conditioned medium and abrogated the reduction in apoptosis in REG Ia transfected cells. These data strongly suggest that REG Ia secreted from epithelial cells or cancer cells exerts growth promoting and antiapoptotic actions in a paracrine or autocrine fashion. On the other hand, it may be noted in this study that colitic cancers develop in only a limited number of patients with UC, although REG Ia is ubiquitously expressed in the inflamed UC mucosa. However, it may be emphasised that carcinogenesis is a complicated event in which many factors are involved. Thus REG Ia may play a role in the UC-colitic cancer sequence as one of the growth promoting as well as antiapoptotic factors, and function in colitic cancer development not as a tumour initiator but as a tumour promoter.
In the present study, we have shown that REG Ia gene expression is increased not only in UC mucosa and colitic cancers but also in sporadic colon adenomas or cancers, using real time RT-PCR analysis, although its expression is not always detected in sporadic colon cancers by northern blot analysis. 16 33 In addition, REG Ia gene expression was detected in all seven colon cancer cell lines examined. These findings may suggest that REG Ia is involved not only in the UC-colitic cancer sequence but also in the adenoma-carcinoma sequence, although the mechanism of carcinogenesis in UC associated colorectal cancer is believed to be distinct from that in sporadic colorectal cancer. 34 35 The role of REG Ia in the adenoma-carcinoma sequence should also be clarified in future studies.
In summary, we have shown that REG Ia is expressed not only in epithelial cells of UC mucosa but also in precancerous dysplastic epithelial cells and colitic cancer cells. The promoter activity of the REG Ia gene is stimulated by IFN-c and IL-6. Moreover, REG Ia protein has both mitogenic and antiapoptotic effects on human colon cancer cells in vitro. Together, these results suggest that cytokine induced REG Ia in the colonic mucosa plays an important role in the development of UC associated colorectal cancer. bmjupdates+ bmjupdates+ is a unique and free alerting service, designed to keep you up to date with the medical literature that is truly important to your practice. bmjupdates+ will alert you to important new research and will provide you with the best new evidence concerning important advances in health care, tailored to your medical interests and time demands.
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